- Home
- » Tags
- » Eltrombopag
Top View
- PDL DRUG REVIEW Proprietary Name: Zeposia® Common Name: Ozanimod PDL Category: Multiple Sclerosis Agents
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- NEW 2018 Specialty Drugs
- The Effect of Eltrombopag in Managing Thrombocytopenia Associated With
- Lumicera Specialty Drug List
- Brand Generic Guide
- Proposed Formulary Changes Effective 4-1-2019 (Unless Otherwise Noted)
- 07 Poster Viewing I 65..65
- The Role of Eltrombopag and Romiplostim As The
- Effect of Cytokine Gene Polymorphisms on Eltrombopag Reactivity in Japanese Patients with Immune Thrombocytopenia
- PROMACTA (Eltrombopag) RATIONALE for INCLUSION IN
- Immunosuppression and Growth Factors for Severe Aplastic Anemia: New Data for Old Questions David J
- Eltrombopag (Revolade) for Severe Aplastic Anaemia – First Line
- Drug Safety Update
- Pharmacy Specialty Drug Policies
- The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation
- JAKAFI® Or PROMACTA®
- Successful Treatment of Secondary Poor Graft Function Post Allogeneic
- Thrombopoietin Receptor Agonists for Use in Hepatitis C Related
- Therapeutic Class Overview Multiple Sclerosis Agents
- Therapy of Posttransplant Poor Graft Function with Eltrombopag
- Eltrombopag for the Treatment of Chronic Immune Thrombocytopenia
- Mitigative Efficacy of the Clinical Dosage Administration Of
- Reimbursement Criteria for Frequently Requested Drugs
- An Oral, Nonpeptide Thrombopoietin Receptor Agonist
- View Our Specialty Medication List
- Attachment 2. Extract from the Clinical Evaluation Report for Eltrombopag
- Interactions with Experimental COVID-19 Therapies
- DTF Prior Authorization Drug List the Following Is a List of the Prescribed
- Myelodysplastic Syndromes
- Orange Book Cumulative Supplement 7 July 2021
- Pathogenesis-Oriented Approaches for the Management of Corticosteroid-Resistant Or Relapsedprimary Immune Thrombocytopenia
- Label Extension Trial [See Clinical Studies (14.1)]
- Avatrombopag (Doptelet®), Eltrombopag (Promacta®), Lusutrombopag (Mulpleta®), Fostamatinib (Tavalisse™) EOCCO POLICY
- The Non-Peptide Thrombopoietin Receptor Agonist Eltrombopag Stimulates Megakaryopoiesis in Bone Marrow Cells from Patients with Relapsed Multiple Myeloma
- INC424/Ruxolitinib a Non-Interventional Long-Term
- Jakavi, INN-Ruxolitinib
- Paragraph IV Patent Certifications (PPIV)
- Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C John G
- Eltrombopag Promacta for Use for Hepatitis C Related
- Prioritisation of Potential Anti-SARS-Cov-2 Drug Repurposing
- Romiplostim and Eltrombopag for Immune Thrombocytopenia: Methods for Indirect Comparison
- Restricted Use – Prior Approval Drug List
- Efficacy, Safety and Immunological Profile of Combining Rituximab With
- Pathophysiology of Autoimmune Thrombocytopenia: Current Insight with a Focus on Thrombopoiesis
- Investor Presentation July 21, 2020 Disclaimer
- The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human
- Coexistence of BCR/ABL1-Positive Chronic Myeloid Leukemia and JAK2
- Specialty Pharmacy Medication List
- Promacta® (Eltrombopag)
- Publication Agenda CHMP 07-10 December 2020
- Use of Eltrombopag Exposure-Platelet Response
- Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia
- Drug Design and Repurposing with Dockthor-VS Web Server
- Revolade, INN-Eltrombopag
- Eltrombopag, a Second-Generation Thrombopoietin Receptor Agonist, for Chronic Lymphocytic Leukemia-Associated ITP
- Revolade Tablets 12.5 Mg and 25 Mg [Nonproprietary Name] Eltrombopag Olamine (JAN*) [Applicant] Glaxosmithkline K.K
- 5.01.566 Pharmacotherapy of Thrombocytopenia
- Eltrombopag Enables Initiation and Completion of Pegylated Interferon
- The Eltrombopag Antitumor Effect on Hepatocellular Carcinoma
- Revolade, INN-Eltrombopag